Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core
Capabilities

BANGALORE, India, March 17 /CNW/ - Infinitus Clinical Research is continuing to pioneer its unique strategy. This is based on the following elements:

    
    -   Physician leadership

    -   Employee ownership

    -   Sino-Indian focus

    -   Flexible co-development model availability

    -   Experience of big Pharma drug development programme planning

    -   Experience of early stage life science company product development

    -   Phase I, II and III capability within Asia for clinical evaluation of
        drugs

    -   Clinical evaluation of medical devices

    -   Clinically focused bioinformatics capability

    -   Unique academic links and collaborations
    

"As former Vice-President for clinical drug development with a major US Pharma company" said CEO, Roy Drucker, "I was frustrated by the unexploited potential of India and China. Large Western CROs were inevitably forced to give up part of the cost advantage of those countries because of operating expense back at base camp. The best local players scored better on price and satisfied study deadline requirements but were incapable of assuming a product development partnership role. We strive to deliver the best of both worlds at Infinitus. "

    
    "Our conviction is that excellent medical science underpins excellent
    	clinical research and education. This is reflected in our ongoing
    collaborative relationship with the Department of Pharmacology at the
    University of Oxford, where we have a Coordinating Centre. We recognize
    that a significant part of our client base is in the USA and our North
    American office will open shortly. We are also progressing a major
    oncology initiative which will enable Infinitus to deliver unparalleled
    speed, quality and prices for studies in all phases."
    

"Infinitus has also recognized the opacity of India and China to smaller Western companies wishing to conduct product or corporate transactions in these countries. With established strategic partners in both locations we are currently working with clients who have products for which they are seeking to achieve marketing presence in India and China, as well as executing M&A mandates on behalf of Western clients. More recently, we have begun to serve the needs of Chinese clients wishing to bring their products to the West."

Roy Drucker: "The world of clinical product development is changing very rapidly and there are huge advantages available to those who are prepared to explore unfamiliar territory. Infinitus can make that exploration a positive experience."

About Infinitus:

Infinitus executes its clinical research activities exclusively in Asia.

Benefitting from not having to bear the overheads of a large western infrastructure, the orientation is very much towards serving the needs of an international clientele which includes early stage life science companies researching pharmaceutical and biotechnology products as well as medical devices.

Operating out of Bangalore in India and Nanjing in China, it is led by a management team with extensive experience of conceiving and executing entire clinical product development programmes for global registration purposes, as well as substantial hands-on operational experience in the relevant territory.

Its objective is to assist in curtailing the cost of product development in its clinical stages while at the same time expediting execution and adding value in every way possible.

    
    Infinitus' product candidate and program evaluation services are used as
    decision support tools by investors prior to investment or to guide
    investment decisions, and by pharmaceutical companies prior to
    committing their resources to clinical programs for candidates developed
    in-house or before in-licensing candidates. It is supported by all
    members of our Scientific Advisory Board.
    

For further information: Media Contact: Dr Shailendra, Tel: [phone], http://www.infinitusglobal.com, E-mail: [email protected], [email protected], [email protected]